NCT04535453View on ClinicalTrials.gov

A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents

PHASE2CompletedINTERVENTIONAL
Enrollment

635

Participants

Timeline

Start Date

August 28, 2020

Primary Completion Date

March 9, 2022

Study Completion Date

March 9, 2022

Conditions
Healthy
Interventions
BIOLOGICAL

Ad26.COV2.S

All participants, both adults and adolescents, will receive intramuscular (IM) injections of Ad26.COV2.S.

OTHER

Placebo

Adult participants in Groups 4, 5, 6, 8, and 10, and adolescent participants in Group C will receive at least one injection of placebo.

Trial Locations (13)

10117

Charité Research Organisation GmbH, Berlin

18057

Universitaetsmedizin Rostock, Rostock

20251

CTC North GmbH & Co. KG, Am Universitätsklinikum Hamburg-Eppendorf, Hamburg

28006

Hosp. Univ. de La Princesa, Madrid

28046

Hosp. Univ. La Paz, Madrid

39008

Hosp. Univ. Marques de Valdecilla, Santander

NZ 9728

PRA Health Sciences, Groningen

2333 CL

Centre for Human Drug Research, Leiden

3584 CX

UMCU, Utrecht

L12 2AP

Alder Hey Hospital, Liverpool

SW17 0RE

St George's, University of London, London

M13 9WL

Royal Manchester Children's Hospital, Manchester

SO166YD

University Hospital Southampton NHS Foundation Trust, Southampton

All Listed Sponsors
lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT04535453 - A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents | Biotech Hunter | Biotech Hunter